An electromyographic study of the responses of the pelvicalyceal border which is the pacemaker region of ureteral peristalsis, and of the renal pelvis and ureter to dobutamine and terbutaline, Β1- and Β2-adrenergic stimulants, respectively, was performed using isolated canine pelviureteral preparations. The Β1-adrenergic stimulant produced a marked enhancement of discharge potential in the pacemaker region, but, in the renal pelvis and ureter, it did not evoke any noticeable response. Application of the Β2-adrenergic stimulant led to disappearance of discharges in the renal pelvis and ureter, whereas the pacemaker region continued to exhibit regular discharges. These findings seem to suggest the presence in the pelvicalyceal border of a group of cells which, unlike other smooth muscle cells, respond to Β-adrenergic agents in a fashion similar to the cardiac pacemaker, namely, stimulated by Β1-adrenergic stimulants and not inhibited by Β2-adrenergic stimulants.

Keywords:
Ureteral peristalsis, Pacemaker, β1-, and β2-adrenergic drugs
This content is only available via PDF.
© 1984 S. Karger AG, Basel
1984
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.